Animal experiment:

The cats are weighed on Days-2, 29 and 58 to calculate the dosing. Cats in group 1 (control group) remain untreated. On Day 0, the cats in group 3 are treated with fluralaner at the minimum recommending label dose of 40.0 mg per kg body weight. On Days 0, 30 and 60, the cats in group 2 are treated with the new spot-on formulation at the minimum recommending label dose of 1.0 mg/kg sarolaner and 6.0 mg/kg Selamectin. The cats are observed at different time points after treatment for possible adverse reactions to treatment. On Day 0, administration site observations are performed on all cats 30 min (±5 min), 3 h (±15 min) and 24 h (±1 h) and again on Days 3 and 5 after treatment[1].

• Pharmacol Res (2020): 104763.

Selamectin is an anthelminthic which can be used on dogs and cats.

Three monthly treatments with Selamectin/sarolaner provide high and consistent efficacy against I. ricinus for the entire duration of the study period. The percentage efficacy against I. ricinus is numerically higher in the Selemectin/sarolaner treating group than in the fluralaner-treating group on Days 56, 84 and 91[1]. All dogs are tested negative by both tests after receiving topical treatment with Selamectin monthly for 36 months[2].

[1]. Thomas Geurden, et al. Comparative efficacy of a new spot-on combination product containing selamectin and sarolaner (Stronghold(R)Plus) versus fluralaner (Bravecto(R)) against induced infestations with Ixodes ricinus ticks on cats. Published online 2017 Jun 29. [2]. Maria de Fátima Chicarino Varajao Moraes-da-Silva, et al. Selamectin for the prevention of canine Dirofilaria immitis infection: field efficacy in client-owned dogs in a high risk area. Published online 2016 Jul 22.